Clinical trial · Interventional
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS Cases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn if drospirenone can work to prevent LH surge in controlled ovarian stimulation in PCOS cases undergoing ART cycles. The main questions it aims to answer are: Can drospirenone prevent LH surge in controlled ovarian stimulation in PCOS cases ? Can it prevent the occurance of ovarian hyperstimulation? Researchers will compare drospirenone to cetrorelix (A well known drug for such cases) to see if drospirenone works the same way. Participants will: Take drospirenone or cetrorelix from stimulation day 5 ( 5 days of ovarian stimulation) till day of hCG trigger \- monitoring will be done before the cycle and through the cycles with vaginal ultrasound assessment and lab testing
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PCOS (Polycystic Ovary Syndrome) | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetrorelix drug | Drug | — | UNRESOLVED |
| Drospirenone drug | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Drospirenone
- description
- 25 cases will receive drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
- interventionNames
- Drug: Drospirenone drug
- type
- ACTIVE_COMPARATOR
- label
- cetrorelix
- description
- 25 cases will receive cetrorelix from day 5 of stimualtion till hCG trigger day
- interventionNames
- Drug: Cetrorelix drug
Primary outcomes (2)
- measure
- number of cases to develop OHSS
- timeFrame
- 1 week
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 38 Years
Show eligibility criteria text
Inclusion Criteria: * PCOS was diagnosed according to the Rotterdam consensus criteria (two out of three of the following criteria): 1. oligo- or anovulation 2. clinical and/or biochemical signs of hyperandrogenism 3. polycystic ovaries). * A diagnosis of congenital adrenal hyperplasia, Cushing's syndrome, androgen-producing tumours, hyperprolactinemia and thyroid dysfunction were all rulled out. Exclusion Criteria: * age 38 years * basal FSH level 12 mIU/mL * previous ovarian surgery * congenital uterine anomaly anomaly, intrauterine adhesion and male partner with non-obstructive azoospermia.
References
Publications (0)
Data not yet available